Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Xenon Pharmaceuticals director Dawn Svoronos reported routine equity compensation activity. Previously granted restricted share units vested into 2,645 Common Shares, and the company withheld 1,416 shares at $53.41 to cover income taxes, which the filing notes does not represent a sale.
Following these transactions, she directly holds 26,229 Common Shares. On the same date, she received new awards of 1,593 restricted share units and options for 10,507 shares with a $53.46 exercise price expiring on June 2, 2036, both vesting in full around the issuer’s 2027 annual meeting of shareholders.
Xenon Pharmaceuticals Inc. reported results of its annual meeting of shareholders held on June 2, 2026. Shareholders approved a new 2026 Equity Incentive Plan to replace the prior 2014 plan, following the Board of Directors’ recommendation.
Shareholder turnout was high, with 90,399,636.29 common shares, representing approximately 93.54% of shares entitled to vote, present or represented by proxy. All director nominees were elected, the advisory "say‑on‑pay" vote on executive compensation was approved, and shareholders supported holding this advisory vote every one year. Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent auditor and authorized the audit committee to set the auditor’s remuneration.
XENON PHARMACEUTICALS INC. Schedule 13G/A reports that Janus Henderson Group plc and its Asset Managers are deemed to beneficially own 4,175,982 common shares, representing 4.5% of the outstanding common stock as reported. The filing clarifies voting and dispositive power is exercised shared by the Asset Managers.
Xenon Pharmaceuticals reports beneficial ownership by Avoro Capital Advisors LLC and Behzad Aghazadeh of 5,777,777 shares of common stock, representing 6.26% of the class. The percentage is calculated using 92,247,633 Common Shares outstanding as reported in the Company’s March 12, 2026 prospectus supplement after the underwriters' overallotment exercise. The filing is an amendment to a Schedule 13G/A that updates ownership details filed by the reporting persons.
Xenon Pharmaceuticals Inc. reports that Driehaus Capital Management LLC beneficially owned 4,491,653 shares of common stock, representing 4.87% of the class as of 12/31/2025. The amendment is signed by the filer’s General Counsel on 05/15/2026.
The filing lists shared voting and dispositive power for the entire position and classifies the holding as ownership of 5 percent or less of the class.
Xenon Pharmaceuticals Inc. director Steven Gannon exercised stock options to acquire 3,500 Common Shares at an exercise price of $7.38 per share. This exercise-and-hold transaction increased his directly held stake to 10,641 Common Shares following the transaction. The underlying stock options were fully vested and exercisable and, after this exercise, no related options in this grant remain outstanding.
Xenon Pharmaceuticals reported a larger net loss as it ramps late-stage development. For the quarter ended March 31, 2026, net loss widened to $102.3 million from $65.0 million a year earlier, driven by higher research and development and general and administrative costs and no milestone revenue.
R&D spending rose to $88.5 million, mainly for Phase 3 programs of azetukalner in epilepsy and depression and early-stage pain programs. Xenon strengthened its balance sheet with $843.0 million of financing cash inflows, including an underwritten equity and pre-funded warrant offering, ending the quarter with $1.34 billion in cash, cash equivalents and marketable securities to fund ongoing clinical trials and potential commercialization.
Xenon Pharmaceuticals reported a larger net loss in Q1 2026 as it ramps late‑stage neuroscience programs but highlighted pivotal clinical progress and a strengthened balance sheet. The company posted a net loss of $102.3 million (vs. $65.0 million a year ago), driven by higher research and development and general and administrative expenses and the absence of prior collaboration revenue.
Cash, cash equivalents, and marketable securities rose to $1.34 billion as of March 31, 2026, after raising $130.0 million via an at‑the‑market program and $707.6 million through a public offering, extending cash runway into 2029. Xenon reported positive Phase 3 X‑TOLE2 data for azetukalner in focal onset seizures, with a placebo‑adjusted median percent change in monthly seizure frequency of -42.7% at 25 mg, and plans a New Drug Application submission in Q3 2026. Multiple additional Phase 3 studies in epilepsy and mood disorders, as well as Phase 1 pain programs targeting NaV1.7 and KV7, continue to enroll or progress.
Xenon Pharmaceuticals Inc. is asking shareholders to vote at a virtual-only annual meeting on June 2, 2026. Holders of common shares as of April 7, 2026 can attend via webcast and have one vote per share on each proposal.
Shareholders will be asked to elect eight directors, approve on an advisory basis executive compensation and the frequency of future say‑on‑pay votes, approve a new 2026 Equity Incentive Plan, appoint PricewaterhouseCoopers LLP as auditor, and authorize the Audit Committee to set auditor remuneration. Directors are elected under a majority‑voting standard in uncontested elections, and quorum requires at least 33⅓% of voting shares present or represented by proxy.
As of the record date, 96,642,822 common shares were outstanding, and non‑voting pre‑funded warrants were exercisable into up to 2,931,293 additional common shares. Two major holders, FMR LLC and Avoro Capital Advisors LLC, beneficially own 9.13% and 5.86% of the common shares, respectively, while all current directors and executive officers together beneficially own 2.91%.